HONG KONG, OrbusNeich today announced that it will host a symposium featuring the COMBO Dual Therapy Stent at the 79^th Annual Meeting of the German Cardiac Society. The symposium, entitled “Novel Stent Strategies: What Are the Advantages for Patients?,” will take place at 1 p.m. CEST on Thursday, April 4, in room 17 UG at the Congress Center Rosengarten Mannheim. 

The event will be chaired by Prof. Dr. Gert Richardt of Segeberger Kliniken Gruppe, Bad Segeberg, Germany, and Prof. Dr. Andreas M. Zeiher of the Division of Cardiology, Department of Medicine III, University Hospital, Frankfurt am Main, Germany.

Agenda

• Introduction – Prof. Dr. Andreas M. Zeiher
• Challenges of Dual Antiplatelet Therapy in Patients with Bleeding and Ischemic Events: A Daily “Real World” Dilemma – Prof. Dr. Jochen Woehrle of the University Hospital Ulm, Germany
• COMBO Dual Therapy Stent: First Clinical Data. What Are the Advantages for Patients? – Prof. Dr. Michael Haude, Lukaskrankenhaus, Neuss, Germany
• Significance of Early Endothelialization for Successful Long-Term Therapy – Prof. Dr. Ulf Landmesser, University Hospital Zurich, Switzerland
• BMS, DES, DTS, BVS – What is the Best Stent for Each Patient? – Prof. Dr. Martin W. Bergmann, Asklepios Klinik St Georg, Hamburg, Germany
• Summary – Prof. Dr. Gert Richardt

“The COMBO Stent is designed to provide the long-term safety of the established Genous™ stent while controlling neointimal proliferation,” said Prof. Dr. Haude. “We have previously seen superb homogenous coverage of the COMBO Stent struts at nine months, which may prove to have a favorable effect on late outcomes for patients versus monotherapy DES.”

Source: OrbusNeich